The bears won the InflaRx debate

For the past few months, in the biotech corners of Wall Street, there’s been a fight over a German drug company called InflaRx. To its supporters, the company’s treatment for a debilitating skin disease looked like a winner. To its detractors, InflaRx’s clinical data suggested a bust in the making.

Yesterday we got the results of a pivotal trial, and it turns out the detractors were right.

As STAT's Adam Feuerstein reports, there was no statistically significant benefit to taking InflaRx’s drug instead of placebo after 16 weeks of treatment. The negative outcome sent InflaRx’s stock price down nearly 90%, justifying the skeptics who never bought into the company’s promise.

Read more.